Compounds > fulvestrant
Page last updated: 2024-08-26

fulvestrant and Bladder Cancer

fulvestrant has been researched along with Bladder Cancer in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Glasgow, M; Murugan, P; Rivard, C; Song, M1
Kase, AM; Menke, D; Tan, W1
Chang, C; Han, R; Hsu, I; Li, Y; Messing, EM; Niu, Y; Shang, Z; Tian, J; Wen, S; Yeh, S; Zhang, M1
Hoffman, KL; Lerner, SP; Smith, CL1
Ayala, GE; Hsieh, JT; Jian, W; Kim, IY; Lerner, SP; Shen, SS; Smith, CL; Sonpavde, G; Younes, M; Yu, J1
Beckmann, K; Beckmann, MW; Lux, MP; Thiel, F; Wenkel, EM1

Reviews

1 review(s) available for fulvestrant and Bladder Cancer

ArticleYear
Breast cancer metastasis to the bladder: a literature review.
    BMJ case reports, 2018, Jun-28, Volume: 2018

    Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cancer Survivors; Carcinoma, Ductal, Breast; Cystoscopy; Estradiol; Fatal Outcome; Female; Fulvestrant; Humans; Middle Aged; Receptor, ErbB-2; Urinary Bladder Neoplasms; Urinary Bladder, Overactive

2018

Other Studies

5 other study(ies) available for fulvestrant and Bladder Cancer

ArticleYear
Aggressive Angiomyxoma of the Vulva and Bladder.
    Obstetrics and gynecology, 2017, Volume: 130, Issue:4

    Topics: Antineoplastic Agents, Hormonal; Diagnosis, Differential; Estradiol; Female; Fulvestrant; Goserelin; Humans; Middle Aged; Myxoma; Neoadjuvant Therapy; Neoplasm Invasiveness; Urinary Bladder Neoplasms; Vulvar Neoplasms

2017
Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer.
    Oncotarget, 2016, May-10, Volume: 7, Issue:19

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Butylhydroxybutylnitrosamine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Integrin alpha5beta1; Interleukin-6; Macrophages; Mice; Neoplasms, Experimental; Treatment Outcome; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms

2016
Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.
    Hormones & cancer, 2013, Volume: 4, Issue:1

    Topics: Apoptosis; Carcinoma, Transitional Cell; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Down-Regulation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Humans; Immediate-Early Proteins; MCF-7 Cells; Poly(ADP-ribose) Polymerases; Raloxifene Hydrochloride; S-Phase Kinase-Associated Proteins; Tamoxifen; Tumor Suppressor Proteins; Urinary Bladder Neoplasms

2013
Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
    Cancer, 2006, Jun-15, Volume: 106, Issue:12

    Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Microarray Analysis; Neoplasm Staging; Raloxifene Hydrochloride; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Urinary Bladder Neoplasms

2006
Fulvestrant: a further treatment option for patients with metastatic uterine cancer?
    Onkologie, 2006, Volume: 29, Issue:12

    Topics: Antineoplastic Agents, Hormonal; Estradiol; Female; Fulvestrant; Humans; Liver Neoplasms; Middle Aged; Receptors, Estrogen; Treatment Outcome; Urinary Bladder Neoplasms; Uterine Neoplasms

2006